Severe Immune‐Related Neurological Adverse Events Associated With Immune Checkpoint Inhibitor Treatment: A Retrospective Single‐Center Study
Schwere immunvermittelte neurologische Nebenwirkungen unter Therapie mit Immun-Checkpoint-Inhibitoren: retrospektive Einzelzentrumsstudie
European Journal of Neurology · 2026-06 · 33 (6)
DOI: 10.1111/ene.70652 ↗Auf einen Blick
In einer monozentrischen Auswertung traten schwere neurologische immunvermittelte Nebenwirkungen unter Immun-Checkpoint-Inhibitoren selten auf. Meist betrafen sie das neuromuskuläre System oder periphere Nerven.
Fragestellung
Wie häufig und in welcher Form traten schwere neurologische immunvermittelte Nebenwirkungen unter Immun-Checkpoint-Inhibitoren auf?
Methode
Retrospektive monozentrische Analyse eines klinikinternen Registers der Medizinischen Universität Wien mit allen mit ICIs behandelten Patient:innen von 2007 bis 2023.
Ergebnisse
Von 2043 gescreenten Patient:innen entwickelten 10 (0,5 %) schwere n-irAEs. Häufig waren Myasthenie/Myositis (n = 5); klinische Besserung bei 7 von 10 Fällen.
Schlussfolgerung der Autor:innen
Die Autor:innen folgern, dass schwere n-irAEs selten sind. Ärzt:innen sollten dennoch auch nach längerer Behandlung auf verzögerte Neurotoxizität achten.
Kernaussagen
- Schwere n-irAEs traten bei 10 von 2043 Patient:innen auf.
- Am häufigsten waren Myasthenie/Myositis sowie neuromuskuläre/periphere Manifestationen.
- Bei 7 von 10 Fällen zeigte sich eine klinische Besserung.
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Neurology, online erschienen am 02.06.2026. Verfasst von Anna Grisold und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Medical University of Vienna, Vienna, Austria. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Nervous System Diseases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Patientensicherheit
Abstract (Originalsprache)
Background
Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of various malignancies. The resulting activation of the immune system may lead to neurological immune‐related adverse events (n‐irAEs). Here, we retrospectively characterized severe n‐irAEs in a monocentric cohort.
Methods
We screened an in‐house registry of the Medical University of Vienna, Austria, including all patients treated with ICIs between 2007 and 2023. Patients who underwent a neurological evaluation were identified, and their medical records were reviewed. Cases with severe (i.e., grade ≥ 3) n‐irAEs were analyzed. We report clinical and demographic characteristics, neurological manifestations, treatment and outcomes.
Results
Ten out of 2043 screened patients (i.e., 0.5%) developed severe n‐irAEs. In most cases ( n = 7), neurological manifestations involved the neuromuscular system and/or peripheral nerves, including myasthenia/myositis ( n = 5), polyneuropathy ( n = 1), and facial nerve palsy ( n = 1). Central nervous system involvement included aseptic meningitis, myelitis, and stroke (each n = 1). The number of ICI cycles prior to n‐irAE onset varied, with a median of 3 cycles (range 1–43). The median time from the last infusion to symptom onset was 7 days (range 2–24). n‐irAEs led to ICI discontinuation and/or immunomodulatory treatments in 9 patients. Clinical improvement was observed in 7 of 10 cases. No deaths were attributed to ICI‐related toxicity.
Conclusion
Our findings indicate that severe n‐irAEs are rare. Nonetheless, clinicians should remain vigilant for delayed‐onset neurotoxicity, even after long treatment exposure. Most patients showed clinical improvement following ICI discontinuation and/or immunomodulatory treatments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Medical University of Vienna, Vienna, Austria.
- Comprehensive Center for Clinical Neurosciences & Mental Health, Medical University of Vienna, Vienna, Austria.
- Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
- Christian Doppler Laboratory for Personalized Immunotherapy, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
- Pharmacy Department, Vienna General Hospital, Vienna, Austria.
- Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
ORCID-Profile: Anna Grisold, Julia M Ressler, Thomas Berger
Zitieren
APA
Grisold, A., Starzer, A. M., Silvaieh, S., Krenn, M., Aretin, M. B., Schmidinger, M., Ressler, J. M., Polterauer, S., Berger, T., Preusser, M., & Berghoff, A. S. (2026). Severe Immune‐Related Neurological Adverse Events Associated With Immune Checkpoint Inhibitor Treatment: A Retrospective Single‐Center Study. European Journal of Neurology, 33(6). https://doi.org/10.1111/ene.70652
Vancouver
Grisold A, Starzer AM, Silvaieh S, Krenn M, Aretin MB, Schmidinger M, et al. Severe Immune‐Related Neurological Adverse Events Associated With Immune Checkpoint Inhibitor Treatment: A Retrospective Single‐Center Study. European Journal of Neurology. 2026;33(6). doi:10.1111/ene.70652
BibTeX
@article{Grisold2026,
author = {Grisold, Anna and Starzer, Angelika M and Silvaieh, Sara and Krenn, Martin and Aretin, Marie-Bernadette and Schmidinger, Manuela and Ressler, Julia M and Polterauer, Stephan and Berger, Thomas and Preusser, Matthias and Berghoff, Anna S},
title = {Severe Immune‐Related Neurological Adverse Events Associated With Immune Checkpoint Inhibitor Treatment: A Retrospective Single‐Center Study},
journal = {European Journal of Neurology},
year = {2026},
volume = {33},
number = {6},
doi = {10.1111/ene.70652}
}
EUVIMED